Intellectual Property
Aug. 6, 2015
Federal Circuit affirms validity of patents for lucrative Allergan drug
Allergan Inc.'s exclusive rights to a lucrative drug were affirmed Tuesday when the U.S. Court of Appeals for the Federal Circuit ruled the company's patents for Lumigan, an eye medication, are valid.




Daily Journal Staff Writer
Allergan Inc.'s exclusive rights to a lucrative drug were affirmed Tuesday when the
U.S. Court of Appeals for the Federal Circuit ruled the company's patents for Lumigan,
an eye medication, are valid.
The three-judge panel affirmed a 2013 ruling by U.S. District Judge Michael H. Schneider
of the Eastern Dist...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In